 Metoprolol
"Metoprolol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
| Descriptor ID |
D008790
|
| MeSH Number(s) |
D02.033.100.624.698.573 D02.033.755.624.698.573 D02.092.063.624.698.573
|
| Concept/Terms |
Metoprolol Succinate- Metoprolol Succinate
- Succinate, Metoprolol
- Metoprolol CR-XL
- CR-XL, Metoprolol
- Metoprolol CR XL
Betaloc- Betaloc
- Betaloc-Astra
- Betaloc Astra
- BetalocAstra
|
Below are MeSH descriptors whose meaning is more general than "Metoprolol".
Below are MeSH descriptors whose meaning is more specific than "Metoprolol".
This graph shows the total number of publications written about "Metoprolol" by people in this website by year, and whether "Metoprolol" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 2 | 0 | 2 | | 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 2 | 3 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2017 | 2 | 0 | 2 | | 2019 | 0 | 2 | 2 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Metoprolol" by people in Profiles.
-
Huck DM, Rosenberg MA, Stauffer BL. Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers. J Hypertens. 2022 05 01; 40(5):1019-1029.
-
Brocker CN, Velenosi T, Flaten HK, McWilliams G, McDaniel K, Shelton SK, Saben J, Krausz KW, Gonzalez FJ, Monte AA. Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites. Hum Genomics. 2020 03 11; 14(1):10.
-
Dalton R, Lee SB, Claw KG, Prasad B, Phillips BR, Shen DD, Wong LH, Fade M, McDonald MG, Dunham MJ, Fowler DM, Rettie AE, Schuetz E, Thornton TA, Nickerson DA, Gaedigk A, Thummel KE, Woodahl EL. Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity. Clin Transl Sci. 2020 01; 13(1):147-156.
-
Dransfield MT, Voelker H, Bhatt SP, Brenner K, Casaburi R, Come CE, Cooper JAD, Criner GJ, Curtis JL, Han MK, Hatipoglu U, Helgeson ES, Jain VV, Kalhan R, Kaminsky D, Kaner R, Kunisaki KM, Lambert AA, Lammi MR, Lindberg S, Make BJ, Martinez FJ, McEvoy C, Panos RJ, Reed RM, Scanlon PD, Sciurba FC, Smith A, Sriram PS, Stringer WW, Weingarten JA, Wells JM, Westfall E, Lazarus SC, Connett JE. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med. 2019 12 12; 381(24):2304-2314.
-
Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ. Bucindolol for the Maintenance of Sinus?Rhythm in a Genotype-Defined HF?Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 07; 7(7):586-598.
-
Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen DJ, Sauer WH, White M, Wilton SB, Anand IS, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. Am Heart J. 2018 05; 199:51-58.
-
Stauffer BL, Dow CA, Diehl KJ, Bammert TD, Greiner JJ, DeSouza CA. Nebivolol, But Not Metoprolol, Treatment Improves Endothelial Fibrinolytic Capacity in Adults With Elevated Blood Pressure. J Am Heart Assoc. 2017 Nov 09; 6(11).
-
Duran JM, Makarewich CA, Trappanese D, Gross P, Husain S, Dunn J, Lal H, Sharp TE, Starosta T, Vagnozzi RJ, Berretta RM, Barbe M, Yu D, Gao E, Kubo H, Force T, Houser SR. Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res. 2014 May 23; 114(11):1700-1712.
-
Ripley TL, Saseen JJ. ?-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother. 2014 Jun; 48(6):723-33.
-
Bakker EJ, Ravensbergen NJ, Voute MT, Hoeks SE, Chonchol M, Klimek M, Poldermans D. A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery; rationale and design of DECREASE-XIII. Eur J Vasc Endovasc Surg. 2011 Sep; 42(3):317-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|